
Pregnant women appear in barely one trial application in a hundred as the medicines regulator launches its women's health programme
The MHRA examined all 4,616 UK clinical trial applications submitted between 2019 and 2023. Pregnant women were represented in 1.1 per cent of them and breastfeeding women in 0.6 per cent. Its new programme, running to 2030, is the regulator's answer.
The Medicines and Healthcare products Regulatory Agency has launched a Women's Health Programme whose purpose is to close the gaps in what is known about how medicines and medical devices work for women. The programme was announced on Monday 16 November, and the analysis behind it is stark: of every hundred UK clinical trial applications the agency examined, pregnant women featured in little more than one.
The count is comprehensive. The MHRA looked at all 4,616 clinical trial applications submitted in the UK between 2019 and 2023. Pregnant women were represented in 1.1 per cent of them. Breastfeeding women were represented in 0.6 per cent. Women make up 51 per cent of the population, the agency noted, yet they have historically been underrepresented in clinical research, which limits the evidence available on medicines and devices during pregnancy and across reproductive health. Needs also remain unmet for conditions that are specific to women, and for conditions that present differently, or fall disproportionately, on women.
The programme document, covering 2026 to 2030, sets out the regulatory side of the response: work to improve the safety and effectiveness of medicines and devices used by women, and to make sure women's needs are better reflected in healthcare research and regulation. The agency places the programme under its Strategy to 2030, one of whose priorities is proactive regulation aimed at evidence gaps and inequalities, and describes the programme as the first part of a wider initiative on health inequalities.

For too long, women’s health has been overlooked.Baroness Gillian Merron, Women's Health Minister
The method is collaborative. The programme will bring patients, researchers, healthcare professionals and industry together to strengthen the evidence base, while the agency maintains its standards of safety, quality and effectiveness. It stresses that medicines and devices are complex products, and that biology, age, pregnancy and other health conditions can all change how a person responds to them. Patients helped shape the programme itself, through the MHRA Patient and Public Community and a focus group run by the Patients Association.
There is an innovation case as well as a fairness case. The agency puts the annual turnover of the UK FemTech sector at nearly 300 million pounds, with technology in development across reproductive health, long-term conditions and healthy ageing. The MHRA says that engaging researchers and innovators early, on better evidence about how benefits and risks may differ for women, is the route by which it wants promising products developed and reaching patients earlier.

Baroness Gillian Merron, the Women's Health Minister, said: “For too long, women’s health has been overlooked.” She said the programme, together with the renewed Women's Health Strategy, would mean better evidence and better treatments. Lawrence Tallon, the MHRA chief executive, said: “Better evidence can help us understand where important differences exist.” Naho Yamazaki of the Health Research Authority welcomed the programme and pointed to the two bodies' joint guidance on developing an Inclusion and Diversity Plan, which asks researchers to consider from the earliest stage of study design how their participants can reflect the people who may benefit.
The programme is how the regulator contributes to the Government's wider ambition on women's health, expressed in the renewed Women's Health Strategy for England, with corresponding work under way in Scotland, Wales and Northern Ireland. The announcement was made at the inaugural DIA-MHRA Global Summit in London on 16 and 17 November, held as part of London Life Sciences Week, and the agency will introduce the programme at a webinar on Wednesday 9 December, from 11am to 12pm. The test of it will be in the trial applications of the next four years: whether the 1.1 per cent figure is the low point it currently appears to be.
None to date. The Journal corrects errors promptly and transparently. Read our corrections policy.


